🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Mr. Sumit Arora, Director, Alniche Lifesciences: Driving Healthcare Evolution with Strategic Vision

VCCircleVCCircle · 1y ago
Mr. Sumit Arora, Director, Alniche Lifesciences: Driving Healthcare Evolution with Strategic Vision
Medial

Mr. Sumit Arora is the Director of Alniche Lifesciences, where he has played a pivotal role in driving the company's growth and expansion in the medical field. With a focus on Nephrology and Critical Care medicine, Alniche Lifesciences has become a leading player in these sectors in India. Mr. Arora's strategic vision has led to the introduction of new divisions, including Gastro, Neuro, and Cardio. He emphasizes the importance of a strong distribution network and personally manages distribution channels to ensure timely delivery of specialized products. Alniche Lifesciences aims to increase the availability of medicines globally, with a focus on Renal Care, Neuro, Cardio, and Critical Care segments. The company has also ventured into pharma manufacturing through EffiKasia Lifesciences. Mr. Arora prioritizes active participation in conferences to stay connected with doctors and keep abreast of scientific developments. The company's future plans include launching new divisions and expanding geographically. Mr. Arora has received recognition for his contributions to the healthcare industry.

ChrysCap-backed Eris Life acquires Biocon Biologics' India formulations business

VCCircleVCCircle · 1y ago
ChrysCap-backed Eris Life acquires Biocon Biologics' India formulations business
Medial

Mumbai-based pharmaceutical company Eris Lifesciences, backed by private equity firm ChrysCapital, is set to acquire Biocon Biologics' India branded formulation business for $150 million. The deal, including insulin brands Basalog and Insugen, is expected to be finalized by 15 April, 2024. Eris aims to strengthen its diabetes care franchise and expand into the oncology and critical care sectors. The acquisition also includes a 10-year supply agreement with Biocon Biologics. This move follows Eris's previous acquisitions in the neuropsychiatry and dermatology sectors. Eris Lifesciences operates with a domestic-branded formulations business model and has a distribution network of over 2,000 stockists and 500,000 chemists.

Practo appoints Jagnoor Singh as chief operating officer

EntrackrEntrackr · 5m ago
Practo appoints Jagnoor Singh as chief operating officer
Medial

Practo appoints Jagnoor Singh as chief operating officer Health services platform Practo has announced the appointment of Jagnoor Singh as its Chief Operating Officer (COO). According to Practo, this appointment aligns with its vision of improving health outcomes while building a profitable, innovative, and user-focused business. Jagnoor will focus on establishing robust processes, ensuring seamless execution, and driving accelerated growth. He will lead go-to-market (GTM) strategies, deepening penetration in existing markets and expanding into new ones. Singh brings over 16 years of leadership experience from Airtel, OYO, Mondelez, and Unacademy. He has deep expertise in sales, marketing, and business development, with a proven track record of implementing structured, scalable processes that enhance execution, optimize operations, and drive exponential growth. In his new role, Jagnoor will work closely with Shashank ND, Co-founder & CEO of Practo, to expand the company’s footprint and accelerate its reach, driving impact in the healthcare sector. Jagnoor Singh, on his appointment as Chief Operating Officer, said, “I am truly honored to join Practo at such a pivotal moment for the healthcare industry. Practo’s focus on improving health outcomes and its tech-first approach resonate deeply with me as we build impactful solutions that benefit both patients and providers. I look forward to contributing to Practo’s journey by building strong teams and implementing strategies that drive sustainable growth.” Practo aims to enhance health outcomes by enabling patients and healthcare providers to make informed decisions. The platform leverages computer science and data science to ensure that every interaction contributes to better health results. Practo claims to operate in 22 countries, connecting over 40 crore patients with more than 500,000 doctors and healthcare providers across more than 700 cities.

IAN Group leads seed round in medtech startup SVASTEK

EntrackrEntrackr · 6m ago
IAN Group leads seed round in medtech startup SVASTEK
Medial

Medtech startup SVASTEK has raised Rs 2 crore in a seed funding round led by IAN Angel Fund. The funds will be utilized to launch the ALLTIP-enabled NIV mask across India, build a distributor network for product availability, expand its clinical application team, and drive awareness through medical conferences and targeted outreach programs, SVASTEK said in a press release. Launched in 2022 by Arita Abrol, SVASTEK is a healthcare startup focused on solving challenges within respiratory and critical care through patented solutions designed for large-scale hospital use. The company aims to empower patient care by addressing critical gaps in existing medical technologies. According to the Delhi-based company, its flagship product, the ALLTIP Technology-enabled NIV mask, offers a groundbreaking solution for continuous non-invasive ventilation while allowing simultaneous nutrition delivery, improving clinical outcomes and reducing malnutrition-related risks in patients on long-term respiratory support. As per market research, the respiratory and critical care market in India is valued at Rs 48,500 crores (about $5.8 billion) and is growing at a CAGR of 8.3%. With plans to expand its product portfolio and geographical footprint, the company aims to establish itself as a global leader in respiratory care, driving innovation, affordability, and accessibility in healthcare.

Download the medial app to read full posts, comements and news.